HERVolution Therapeutics logo

HERVolution Therapeutics logo

Findings demonstrate HERV-K is required for senescence-associated inflammation in metabolically challenged cells and is reactivated in plasma of subjects living with obesity

COPENHAGEN, Denmark and NEW YORK, July 15, 2026 /PRNewswire/ -- HERVolution Therapeutics ApS, a biotechnology company pioneering human endogenous retrovirus (HERV)-targeting immunotherapies for oncology, metabolic diseases, and longevity, today announced an oral presentation featuring new scientific data at the International Congress on Obesity (ICO 2026), taking place July 15-17, 2026, in Mexico City. The presentation, titled "Human Endogenous Retrovirus K drives and spreads metabolic senescence," is scheduled for Thursday, July 16, 2026, 16:30–18:00 local time.

Originally published on the BLOX Digital Content Exchange.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.